Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis

References

• Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–1761.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018;68(6):1129–1136.
   PubMed Web of Science ®Google Scholar
• Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–2324.
   PubMed Web of Science ®Google Scholar
• Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52(2):176–182.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62–72.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91–100.
   PubMed Web of Science ®Google Scholar
• Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19(10):732–743.
   PubMed Web of Science ®Google Scholar
• Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35(6):674–689.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Yasuda S, et al. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus–related decompensated cirrhosis. J Viral Hepat. 2021;28(3):508–516.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809–1820.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J Hepatol. 2022;76(1):202–207.
   PubMed Web of Science ®Google Scholar
• Xu XY, Ding HG, Li WG, et al. Chinese guidelines on the management of liver cirrhosis (abbreviated version). World J Gastroenterol. 2020;26(45):7088–7103.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang H, Zhao W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study. BMJ Open. 2021;11(6):e043083.
   PubMed Web of Science ®Google Scholar
• Balcar L, Semmler G, Pomej K, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. United Eur Gastroenterol J. 2021;9(4):427–437.
   PubMed Web of Science ®Google Scholar
• Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther. 2022;55(1):83–96.
   PubMed Web of Science ®Google Scholar
• de Franchis R, Bosch J, Garcia-Tsao G, et al. BAVENO VII - RENEWING CONSENSUS iN PORTAL HYPERTENSION: Report of the baveno VII consensus workshop: personalized care in portal hypertension. J Hepatol. 2022;76(4):959–974.
   PubMed Web of Science ®Google Scholar
• Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the world health organization. J Clin Pathol. 1978;31(5):395–414.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology. 2017;65(1):310–335.
   PubMed Web of Science ®Google Scholar
• Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–1437.e1-9.
   PubMed Web of Science ®Google Scholar
• Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73(4):842–854.
   PubMed Web of Science ®Google Scholar
• Ju YC, Jun DW, Choi J, et al. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World J Gastroenterol. 2018;24(40):4606–4614.
   PubMed Web of Science ®Google Scholar
• Chang ML, Cheng JS, Chien RN, et al. Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18(9):2064–2072.e2.
   PubMed Web of Science ®Google Scholar
• Lee HW, Yip TC, Tse YK, et al. Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2021;19(9):1950–1958.e7
   PubMed Web of Science ®Google Scholar